Literature DB >> 23903212

Trial watch: phase II and phase III attrition rates 2011-2012.

John Arrowsmith, Philip Miller.   

Abstract

Mesh：

Year:  2013        PMID： 23903212     DOI： 10.1038/nrd4090

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  168 in total

1.  NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.

Authors:  Alan P Venook; Maria E Arcila; Al B Benson; Donald A Berry; David Ross Camidge; Robert W Carlson; Toni K Choueiri; Valerie Guild; Gregory P Kalemkerian; Razelle Kurzrock; Christine M Lovly; Amy E McKee; Robert J Morgan; Anthony J Olszanski; Mary W Redman; Vered Stearns; Joan McClure; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2014-11       Impact factor: 11.908

2.  Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis.

Authors:  Yuji Shirai; Shingo Oda; Sayaka Makino; Koichi Tsuneyama; Tsuyoshi Yokoi
Journal:  Lab Invest       Date:  2017-03-06       Impact factor: 5.662

3.  Drug repurposing and beyond: the fundamental role of pharmacology.

Authors:  Diana Amantea; Michelangelo Certo; Giacinto Bagetta
Journal:  Funct Neurol       Date:  2015 Jan-Mar

4.  Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.

Authors:  Tapan K Bera; Wenlong Liu; Jasmin Leshem; Emily King; Serguei Kozlov; Ira Pastan
Journal:  J Immunother       Date:  2019-05       Impact factor: 4.456

5.  High accuracy in silico sulfotransferase models.

Authors:  Ian Cook; Ting Wang; Charles N Falany; Thomas S Leyh
Journal:  J Biol Chem       Date:  2013-10-15       Impact factor: 5.157

6.  A pumpless body-on-a-chip model using a primary culture of human intestinal cells and a 3D culture of liver cells.

Authors:  Huanhuan Joyce Chen; Paula Miller; Michael L Shuler
Journal:  Lab Chip       Date:  2018-07-10       Impact factor: 6.799

Review 7.  [Establishment of a living biobank : Improved guidance of precision cancer care with in vitro and in vivo cancer models].

Authors:  C Pauli; H Moch; M A Rubin
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

8.  The support of human genetic evidence for approved drug indications.

Authors:  Matthew R Nelson; Hannah Tipney; Jeffery L Painter; Judong Shen; Paola Nicoletti; Yufeng Shen; Aris Floratos; Pak Chung Sham; Mulin Jun Li; Junwen Wang; Lon R Cardon; John C Whittaker; Philippe Sanseau
Journal:  Nat Genet       Date:  2015-06-29       Impact factor: 38.330

9.  Focusing on Relevance: CETSA-Guided Medicinal Chemistry and Lead Generation.

Authors:  Stina Lundgren
Journal:  ACS Med Chem Lett       Date:  2019-04-05       Impact factor: 4.345

10.  Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Authors:  Dhiraj Kumar; Ala Lisok; Elyes Dahmane; Matthew McCoy; Sagar Shelake; Samit Chatterjee; Viola Allaj; Polina Sysa-Shah; Bryan Wharram; Wojciech G Lesniak; Ellen Tully; Edward Gabrielson; Elizabeth M Jaffee; John T Poirier; Charles M Rudin; Jogarao Vs Gobburu; Martin G Pomper; Sridhar Nimmagadda
Journal:  J Clin Invest       Date:  2019-01-07       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.